Sinopharm | Sustainability Performance
Provides pharmaceutical products, healthcare solutions, and medical supply distribution. Offers integrated services including logistics, regulatory support, and clinical partnerships. Maintains a portfolio spanning medicines, medical devices, and research collaborations to support healthcare systems.
2003
China
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#536
Overallⓘ#15
in Chinaⓘ#16
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Leading
Laggard
Critical
Controversy level
- Sinopharm Group Co Ltd, Chinese statecontrolled major pharmaceutical (CNPGC parent, COVID19 vaccine major), has faced sustained Chinese NMPA enforcement scrutiny over the contested historic Sinopharm BBIBPCorV COVID19 vaccine efficacy data disclosure disputes, plus periodic class actions over alleged inadequate disclosure of pharmaceutical distribution customer concentration affecting Hong Konglisted institutional shareholders.
